# Elysium Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elysium-health

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.elysiumhealth.com
- Total disclosed funding: $20M
- Latest round: Series C (Dec 23, 2019)
- Investors on record: 6

## About

Elysium Health, Inc. is a biotechnology company focused on formulating health supplements that support healthy aging through scientific research and clinical trials.Founded in 2014 and headquartered in New York, US, Elysium Health, Inc. specializes in health supplement development. The company has raised a total of USD 20.00 mn, with the most recent funding round being a Venture Debt of USD 5.00 mn led by Silicon Valley Bank on December 23, 2019. The founders of the company are Dan Alminana, Eric Marcotulli, and Leonard Guarente, with Eric Marcotulli currently serving as CEO.Elysium Health specializes in developing health supplements aimed at promoting healthy aging. The company's core offerings include Basis, a NAD+ supplement designed to support cellular health and metabolic function; Cofactor, which combines collagen and NAD+ to enhance skin health; and Mosaic, a product aimed at addressing skin aging. These products are formulated based on extensive scientific research and are supported by ongoing human clinical trials. Elysium Health's customer base primarily consists of health-conscious consumers in North America and Europe who are interested in longevity and wellness. The company employs a direct-to-consumer sales model, allowing users to purchase products through its online platform, enhancing accessibility and convenience for end users.Elysium Health generates revenue primarily through direct sales of its supplements via a subscription model, enabling customers to receive regular shipments of their chosen products. The firm's flagship products, including Basis, Cofactor, and Mosaic, are marketed as premium health solutions, appealing to consumers willing to invest in their long-term health. Revenue transactions occur on a recurring basis, as customers can opt for monthly or quarterly subscriptions that provide continuous access to the products. The company has established a reputation for quality, supported by certifications like NSF for sport and third-party testing for purity and quality. This transactional framework enhances customer loyalty and contributes to a stable revenue stream for Elysium Health.Elysium Health plans to expand its product line with new offerings designed to enhance health and wellness. The company is targeting further expansion into international markets, particularly in Europe and Asia, by late 2021. The recent Venture Debt financing will support these growth initiatives, enabling the company to increase its product development efforts and marketing outreach in the new regions. The funding round is part of a larger USD 40 mn Series C and venture debt funding, aimed at bolstering Elysium Health's market presence.

## Funding rounds

- Series C, Dec 23, 2019 — Mayo Clinic Ventures, General Catalyst Partners, 5Y Capital, Breyer Capital, Gisev Family Office
- Series B, Oct 27, 2016, $20M — General Catalyst Partners
- Seed, Dec 1, 2015 — TYLT Ventures

## Investors

- TYLT Ventures (https://capitalatlas.ai/funds/tylt-ventures) — Seed
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B, Series C
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series C
- Gisev Family Office — Series C